Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Treatments: Atazanavir Sulfate; Lamivudine; Lamivudine, zidovudine drug combination; Lopinavir; Zidovudine

Criteria

Inclusion Criteria:

• Age > 18

• HIV exposure requiring prophylaxis under current guidelines

Exclusion Criteria:

• Pregnancy

• Suspected drug resistance in source case

• Contraindications to the study drugs